Maxcyte Q3 2026 Results: Net Loss of $4.76M, Loss Narrows
MaxCyte reported revenue of $10.2 million for the third quarter of 2026, a significant increase from $6.8 million in the prior year period. The company successfully reduced its quarterly net loss to $4.8 million from $12.4 million year-over-year, driven by higher gross profits and a substantial reduction in operating expenses across R&D and sales and marketing.
- Key figure
- Net loss $4.76M